VivoSeq
Other

Platelet Inhibition

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Platelet Inhibition is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Completed10 · 59%
Unknown status3 · 18%
Terminated2 · 12%
Not yet recruiting1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
Active, not recruiting·FFundación EPIC·Phase 4·NCT04654052·634 enrolled
Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head
Not yet recruiting·GGerman Cancer Research Center·Phase 2·NCT05637567·170 enrolled
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
Completed·LLes Laboratoires des Médicaments Stériles·Phase 4·NCT01509365·116 enrolled
Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis
Completed·UUppsala University·Phase 2·NCT00914368·450 enrolled
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
Completed·FFederico II University·Phase 3·NCT04739384·50 enrolled
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
Completed·UUniversity of Florida·Phase 4·NCT03247738·50 enrolled
Platelet Inhibition by Aspirin, Acetaminophen and NSAID
Completed·—·N/A·NCT00536068·11 enrolled
Optimum Platelet Inhibition After Coronary Bypass Surgery
Completed·PPapworth Hospital NHS Foundation Trust·N/A·NCT00262275
Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition
Completed·UUniversity Heart Center Freiburg - Bad Krozingen·N/A·NCT00302913·120 enrolled
Maintenance of Platelet Inhibition With Cangrelor
Completed·Novartis logoNovartis·Phase 2·NCT00767507·221 enrolled
Platelet Inhibition and Transcranial Doppler (TCD)-Detected Microemboli During and After Carotid Artery Stenting (CAS) in Asymptomatic Patients Prior to Cardiac Surgery
Completed·RR&D Cardiologie·Phase 4·NCT01146301
Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel
Completed·SShenyang Northern Hospital·Phase 4·NCT00405717·1,300 enrolled
Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin
Terminated·DDr. med. Mahir Karakas·Phase 3·NCT03820466·68 enrolled
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
Terminated·Novartis logoNovartis·Phase 3·NCT00385138·5,364 enrolled
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI
Unknown status·UUniversity of Aarhus·Phase 4·NCT03182855·80 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)